Acute Montelukast in Asthma
Launched by UNIVERSITY OF EAST ANGLIA · Nov 10, 2009
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute Asthma exacerbation requiring hospitalisation
- Exclusion Criteria:
- • Smoking history greater than or equal to 10 pack years
- • Presenting PEFR greater than or equal to 75% predicted / best
- • Failure to demonstrate greater than or equal to 15% variability in PEFR or FEV during the study
- • Any significant and active pulmonary pathology other than asthma
- • Pregnancy or breastfeeding
- • Intended pregnancy or inability to take adequate precautions against conception
- • Patient already on Montelukast
- • Patient already on Phenobarbitone
- • Patient already on Rifampicin
- • Patient already on Phenytoin
- • Chronic airflow limitation
About University Of East Anglia
The University of East Anglia (UEA) is a prominent research institution located in Norwich, UK, known for its commitment to advancing knowledge and innovation in various fields, including health sciences. UEA fosters a collaborative environment that integrates academic research with clinical practice, enabling the development and execution of high-quality clinical trials. With a focus on improving patient outcomes, UEA engages in interdisciplinary research and partnerships with healthcare providers, ensuring that its clinical trials are designed to address pressing health challenges while adhering to rigorous ethical standards and regulatory requirements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norwich, , United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials